ArticleF1000 medicine reports2011
Cancer, stem cells and cancer stem cells: old ideas, new developments.
Article in F1000 medicine reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Cancer Stem Cells and Their Therapeutic Usage.Advances in experimental medicine and biology · 2023Article
- Antioxidants for the Treatment of Breast Cancer: Are We There Yet?Antioxidants (Basel, Switzerland) · 2021Review
- CSC Radioresistance: A Therapeutic Challenge to Improve Radiotherapy Effectiveness in Cancer.Cells · 2020Review
- Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint.Frontiers in genetics · 2017Review
- Inhibition of c-Yes induces differentiation of HT-29 human colon cancer stem cells through midbody elongation.Tissue engineering and regenerative medicine · 2016Article
- ALDH1 might influence the metastatic capability of HeLa cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Ectopic expression of the WWOX gene suppresses stemness of human ovarian cancer stem cells.Oncology letters · 2015Article
- PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.Cell death & disease · 2014Article
- Deacetylation by SIRT1 Reprograms Inflammation and Cancer.Genes & cancer · 2013Article
- Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population.PloS one · 2013Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been suggested that, at least in some forms of cancer, a sub-population of slow-cycling, therapy-resistant cancer stem cells exists that has the ability to reconstitute the tumor in its entirety. If true, this model implies that conventional therapies based on targeting highly cycling cells within the tumor will leave the slow-cycling stem cell population intact, giving them the opportunity to reinitiate the tumor at a later date. This review discusses the evidence for this model and the likely implications for cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.